A Study of ST-1898 for Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma Clinical Trial

Official title:

A Phase Ib/II Study to Evaluate the Efficacy and Safety of ST-1898 in Subjects With Unresectable or Metastatic Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06359860
• Other study ID #: ST-1898-203
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 7, 2023
• Est. completion date: September 2025

Study information

• Verified date: November 2023
• Source: Beijing Scitech-Mq Pharmaceuticals Limited
• Contact: Jun GUO, MD
• Phone: 086-10-88121122
• Email: guoj307[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma. In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine Recommended Phase 2 dose (RP2D) of ST-1898 tablets in subjects with unresectable or metastatic melanoma. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy. In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma. The secondary objective is to evaluate the safety of ST-1898 tablets.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years
• Life expectancy of three months or more
• Histologically or cytologically confirmed unresectable or metastatic stage III or IV melanoma that was progressed with conventional therapy
• Recommendation of subjects offering archived tissue sample or previous gene test report;
• Eastern Cooperative Oncology Group performance status (PS) = 1
• At least one measurable lesion per RECIST 1.1
• Has adequate organ function defined as follows:

1. Absolute neutrophil count = 1.5 ×109/L, Platelets = 90 × 109/L and Hemoglobin = 90 g/L ( no blood transfusions and no use of CSF within 2 weeks prior to routine blood test) at screening;

2. Serum creatinine =1.5 × upper limit of normal (ULN)

3. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 ULN, AST/ALT = 5 ULN for liver metastasis;

4. Total bilirubin = 1.5 ULN

5. International normalized ratio (INR) = 1.5 ULN, or prothrombin time (PT) =1.5 ULN

6. Activated partial thromboplastin time (APTT) =1.5 ULN

7. Serum albumin =30 g/L

• Willing and able to provide written Informed consent.
• Eligible male and female subjects with fertility activity or their sexual partners must use effective contraception during study period and though 90 days after last study treatment. Women of child-bearing age must have a negative serum pregnancy test within 7 days before first study treatment

Exclusion Criteria:

• Subjects with one of the following conditions prior to first dose, including, but not

limiting to:

• A history of antitumor therapy within 4 weeks, including chemotherapy, radiotherapy, biotherapy, endocrine therapy or immunotherapy, etc.;
• A history of oral fluoropyrimidines and small molecular targeted-drug therapy within 2 weeks or 5 half-life time (the longer time taken as final);
• A history of traditional Chinese medicine with antitumor indication within 2 weeks;
• A history of being participant in clinical trial of other unapproved drugs within 4 weeks;
• A major operation or severe trauma history within 4 weeks, except tumor biopsy, puncture, invasive dental procedures such as dental extraction, dental implants etc.
• Current or previous severe retinopathy who, in the judgment of the Investigator or specialist, are not suitable for enrollment
• A history of clinically significant cardiovascular or cerebrovascular disease,

including, but not limiting to:

• Severe arrhythmia or heart conduction disturbance, such as second-degree or third-degree atrio-ventricular block or ventricular arrhythmia indicated with medical intervention
• QTc (by Fridericia): male >450 ms, female >470 ms
• Major cardiovascular events within 6 months prior to first dose, including acute coronary syndrome, stroke, deep vein thrombosis, pulmonary-thromboembolism and other =Grade 3 arterial-thrombosis events, or congestive heart failure, or aortic dissection etc.;
• New York Heart Association Class = II;
• Left ventricular ejection fraction(LVEF)<50%;
• Uncontrolled hypertension ( blood pressure=140/90 mmHg even with antihypertensive therapy)
• Subjects with active leptomeningeal disease or brain metastases without being well controlled, except subjects with asymptomatic or treated brain metastases being stable imaging between 12 weeks before screening;
• Subjects with interstitial lung disease or radiation pneumonia in needs of corticosteroids therapy
• Subjects with clinically uncontrolled third interstitial effusion within 7 days prior to first dose;
• Subjects with previous or currently malignant tumors (not including non-melanoma skin cancer, breast cancer or cervical cancer in situ, and superficial bladder transient cell carcinoma under control in the last 5 years)
• A history of = grade 3 bleeding episodes within 6 months prior to first dose; or currently = grade 2 hemorrhage, with angioneoplasm/ vascular malformation, with high bleeding risks (such as active gastritis/duodenal ulcer or esophageal varices)
• A history of concomitant medication with strong inducers or inhibitors of CYP3A4 within 2 weeks prior to first dose;
• Subjects with = Grade 2 (by CTCAE) toxicities caused by previous therapy (not including =Grade 2 peripheral neuropathy, alopecia, or other tolerated and no possible safety hazard events as determined by the investigator);
• Subjects with active hepatitis B, unless HBV-DNA titer=the lower limit of the reference range (for subjects with positive HBsAg but HBV-DNA titer eligible, prophylactic antiviral therapy except interferon are allowed); active hepatitis C (antibody positive);
• Subjects with acute bacterial, viral or fungal infections, and in needs of systemic antimicrobial therapy;
• Subjects with positive HIV antibodies or Treponema pallidum antibodies;
• Pregnant or lactating females;
• Subjects with significant neuropsychiatric disorders, leading to poor compliance;
• Subjects with underlying diseases (including abnormal laboratory investigations), alcohol, drug abuse, or drug dependence, all which affect the interpretation of toxicities or adverse event, or decrease;
• Subjects with oral administration impossible, or in the conditions of malabsorption as determined by the investigator, such as dysphagia and intestinal obstruction, etc.;
• Subjects with significant liver cirrhosis, hepatography, portal hypertension, or more than moderate volume of ascites;
• A history of organ transplant;
• A history of other severe systemic disease, or not suitable as determined by the investigator due to any other reasons;
• A history of inoculation with live vaccine within 28 days prior to first dose.

Related Conditions & MeSH terms

• Melanoma
• Unresectable or Metastatic Melanoma

Intervention

Drug:
• ST-1898 tablets
Supplied as 5 mg and 40 mg tablets

Locations

Country	Name	City	State
China	Peking University Cancer Hospital & Institute	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Scitech-Mq Pharmaceuticals Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ib Dose Escalation: The Number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs)	AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0	Approximately 18 months
Primary	Phase Ib Dose Escalation: Recommended Phase 2 Dose (RP2D)	RP2D was determined according to MTD. MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first cycle (21days) of treatment.	Within the first cycle (21days)
Primary	Phase II Expansion: Objective Response Rate (ORR)	ORR is defined as the percentage of participants who experience a CR or PR based on RECIST 1.1 (CR: Complete Response, Disappearance of all target lesions, PR: Partial Response, At least a 30% decrease in the sum of diameters of target lesions)	Approximately 18 months
Secondary	Phase Ib Dose Escalation: Trough concentration of ST-1898	To assess plasma pharmacokinetics (PK) of oral administration of ST-1898	Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks
Secondary	Phase Ib Dose Escalation: Peak concentration of ST-1898	To assess plasma pharmacokinetics (PK) of oral administration of ST-1898	Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase Ib Dose Escalation (21 days per cycle), up to 10 weeks
Secondary	Phase Ib Dose Escalation: ORR	Objective Response Rate (ORR) per RECIST 1.1	Approximately 18 months
Secondary	Phase Ib Dose Escalation: PFS	Progression-Free Survival (PFS) per RECIST 1.1	Approximately 18 months
Secondary	Phase Ib Dose Escalation: DoR	DoR Duration of Response (DoR) per RECIST 1.1	Approximately 18 months
Secondary	Phase Ib Dose Escalation: DCR	Disease Control Rate (DCR) per RECIST 1.1	Approximately 18 months
Secondary	Phase Ib Dose Escalation: TTP	Time to Progression per RECIST 1.1	Approximately 18 months
Secondary	Phase II Dose Expansion: The Number and frequency of treatment-related adverse events and serious adverse events (SAEs)	The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.	Approximately 18 months
Secondary	Phase II Dose Expansion: Trough concentration of ST-1898	To assess plasma Trough concentration of oral administration of ST-1898 in subjects with unresectable or metastatic melanoma	Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks
Secondary	Phase II Dose Expansion: Peak concentration of ST-1898	To assess plasma Peak concentration of oral administration of ST-1898 in subjects with unresectable or metastatic melanoma	Cycle 1 Day 1, Cycle 1 Day 21, Cycle 3 Day 1 during Phase II Dose Expansion (21 days per cycle), up to 10 weeks
Secondary	Phase II Dose Expansion: PFS	Progression-Free Survival (PFS) per RECIST 1.1	Approximately 18 months
Secondary	Phase II Dose Expansion: DoR	DoR Duration of Response (DoR) per RECIST 1.1	Approximately 18 months
Secondary	Phase II Dose Expansion: DCR	Disease Control Rate (DCR) per RECIST 1.1	Approximately 18 months
Secondary	Phase II Dose Expansion: TTP	Time to Progression per RECIST 1.1	Approximately 18 months